Agnieszka Skonieczna, Senior Pharmaceutical Analyst, PMR
In 2017, the segment of reimbursed drugs grew more rapidly than the segment of non-reimbursed Rx drugs, which represented a reversed 2016 trend. This resulted from the low base from the previous year and continued increase in sales of drugs which received positive reimbursement decisions over the past two years, as well as including new substances in the list under the Program 75+ scheme.
In turn, the segment of reimbursed drugs was negatively affected by the fact of subsequent shifts of substances to the inpatient segment (products containing pegfilgrastim and lipegfilgrastim) and price reductions owing…
CAGR for pharmacy market will stand at about 5% in 2017-2022
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)